Prelude Therapeutics (PRLD)
(Delayed Data from NSDQ)
$3.45 USD
-0.15 (-4.17%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $3.41 -0.04 (-1.16%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Prelude Therapeutics Incorporated (PRLD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.80 | $10.00 | $3.00 | 61.11% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Prelude Therapeutics Incorporated comes to $5.80. The forecasts range from a low of $3.00 to a high of $10.00. The average price target represents an increase of 55.5% from the last closing price of $3.73.
Analyst Price Targets (5 )
Broker Rating
Prelude Therapeutics Incorporated currently has an average brokerage recommendation (ABR) of 2.74 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 2.34 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, two are Strong Buy, representing 40% of all recommendations. A month ago, Strong Buy represented 40%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 2 | 2 | 2 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 1 | 1 | 0 | 0 | 0 |
ABR | 2.74 | 2.74 | 2.34 | 2.34 | 2.34 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/20/2024 | Not Identified | Not Identified | Hold | Strong Sell |
3/13/2024 | JMP Securities | Reni Benjamin | Not Available | Strong Buy |
3/12/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/20/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.74 |
ABR (Last week) | 2.74 |
# of Recs in ABR | 5 |
Average Target Price | $5.80 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 98 of 252 |
Current Quarter EPS Est: | -0.46 |